Reshape Lifesciences Inc. (Nasdaq: RSLS) on Thursday reached a new 52-week minimum midday trading. The company traded at the lowest price of $ 1.41, and the last traded at $ 1.53, with a volume of 8571 shares. The stock was previously closed at $ 1.83.
The RSLS is the subject of a large number of recent research reports. On Thursday, October 4, Zacks Investment Research informed Reshape Lifesciences of the rating "hold" for the rating "hold" in the survey. ValuEngine dropped Reshape Lifesciences from rating "bui" to a rating "hold" in the survey on Tuesday, October 2nd. In the end, LADENBURG THALM / SH SH reduced Reshape Lifesciences from rating "buoy" to "neutral" rating in the survey on Friday, August 3rd.
Reshape Lifesciences (Nasdaq: RSLS) was the last to announce earnings results on Tuesday, August 14th. The medical device company reported ($ 672.00) per earnings per share (EPS) for a quarter, missing analysts' consensus estimates ($ 250.60) for ($ 421.40). Reshape Lifesciences had a negative net margin of 2.397,35% and a negative return on equity of 70.96%. The company had an income of $ 0.65 million during the quarter. On average, analysts predict that Reshape Lifesciences Inc. announce -371.83 earnings per share for the current fiscal year.
The hedge fund recently acquired a new stake in Reshape Lifesciences stock. Renaissance Technologies LLC acquired a new stake in Reshape Lifesciences Inc. in the third quarter. (NASDAQ: RSLS), according to the company's data in the latest 13F filing at the Securities and Exchange Commission. The company bought 2,287,729 shares of the company for medical devices, worth about $ 101,000. Renaissance Technologies LLC owns about 3,812.88% of Reshape Lifesciences from its latest SEC filing. 5.68% of shares are currently owned by institutional investors and hedge funds.
WARNING: This content content was reported by Fairfield Current and owned by Fairfield Current. If you access this section of content on a different domain, it is copied unlawfully and redistributed contrary to US and international copyright and trademark laws. The original version of this content can be viewed at https: //vvv.fairfieldcurrent.com/2018/11/16/reshape-lifesciences-rsls-hits-nev-52-veek-lov-at-1-41. html.
About Reshape Lifesciences (NASDAQ: RSLS)
ReShape Lifesciences Inc., a medical device company, focuses on the design and development of devices that use neuroblock technology to treat obesity, metabolic diseases and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to interrupt the vagal nerve by interrupting using electrical impulses.
Recommended Story: How Inflation Affects Different Investments?
You receive news and ratings for Reshape Lifesciences Daili – Enter your email address below to get a concise daily review of the latest news and analysts for Reshape Lifesciences and related companies with FREE Daily MarketBeat.com email.